EMTK:IDXPT Elang Mahkota Teknologi Tbk Analysis
Data as of 2026-05-22 - not real-time
IDR 635.00
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
PT Elang Mahkota Teknologi’s stock is trading at IDR 635, well below its 20‑day (IDR 761.75), 50‑day (IDR 792.30) and 200‑day (IDR 1,048.68) moving averages, signaling a strong bearish technical backdrop. The RSI of 23 indicates the shares are oversold, yet the MACD remains in a bearish configuration with the line below the signal, and volume has been decreasing, reinforcing downside pressure. Volatility is elevated at roughly 47% over the past 30 days, though the beta is low, suggesting limited systematic market risk. On the fundamentals side, revenue surged 47.6% year‑on‑year and profit margins sit at a respectable 13.4%, but the company carries a high debt‑to‑equity ratio of 4.5 and posted negative free cash flow, raising concerns about financial stability. The trailing P/E of 13.8 looks reasonable, but a forward P/E of 96.6 reflects a sharp earnings outlook decline, while the DCF‑derived fair value of about IDR 1,249 points to a substantial intrinsic undervaluation.
The recent announcement that EMTK will not distribute dividends for FY2025 undermines the attractiveness of its historically high 5.7% yield and questions dividend sustainability. Given the blend of strong top‑line growth, significant leverage, and a pending dividend cut, short‑term pressure is likely to persist, but the sizable gap between market price and intrinsic value could present a longer‑term buying opportunity if the company can improve cash generation and reduce debt.
The recent announcement that EMTK will not distribute dividends for FY2025 undermines the attractiveness of its historically high 5.7% yield and questions dividend sustainability. Given the blend of strong top‑line growth, significant leverage, and a pending dividend cut, short‑term pressure is likely to persist, but the sizable gap between market price and intrinsic value could present a longer‑term buying opportunity if the company can improve cash generation and reduce debt.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- Price below all major moving averages
- Bearish MACD and decreasing volume
- Dividend suspension reducing near‑term yield
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Robust revenue growth and solid profit margins
- Significant intrinsic undervaluation versus market price
- High leverage and negative free cash flow limiting upside
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- DCF fair value suggests large upside potential
- Diversified business segments (media, digital, healthcare, aviation)
- Opportunity to improve capital structure and restore dividend
Key Metrics & Analysis
Financial Health
Revenue Growth47.60%
Profit Margin13.43%
P/E Ratio13.8
ROE9.00%
ROA1.19%
Debt/Equity4.51
P/B Ratio1.1
Op. Cash FlowIDR2101.4B
Free Cash FlowIDR-287386501120
Industry P/E17.1
Technical Analysis
TrendBearish
RSI23.2
SupportIDR 635.00
ResistanceIDR 890.00
MA 20IDR 761.75
MA 50IDR 792.30
MA 200IDR 1,048.68
MACDBearish
VolumeDecreasing
Fear & Greed Index91.5
Valuation
Fair ValueIDR 1,248.65
GradeUndervalued
TypeBlend
Dividend Yield5.67%
Risk Assessment
Beta0.18
Volatility47.41%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.